首页> 外文期刊>Journal of drug targeting >Potential use of aptamers for diagnosis and treatment of pancreatic cancer
【24h】

Potential use of aptamers for diagnosis and treatment of pancreatic cancer

机译:潜在使用适体进行胰腺癌的诊断和治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Pancreatic cancer (PC) is highly malignant with a low 5-year survival rate. PC currently does not have good early diagnostic markers and responses poorly to chemotherapeutic drugs. The search for better bio-markers and developing more effective chemotherapy are important ways to improve the healthcare of PC patients. Aptamers are single-stranded nucleic acids with high binding affinity and specificity to target molecules. Many aptamers against different forms of cancer including PC have been selected for both diagnostic and therapeutic use. Aptamers can work as ligands to distinguish tumour cells from normal cells. Using cells as selection targets, the obtained aptamers have been used to discover new cancer bio-markers after identification of the binding target. Aptamers have been shown to have antagonists effect on cancer cell proliferation, apoptosis, and metastasis. In addition, aptamers have been used as carriers to deliver therapeutic agents to selectively kill PC cells. This review summarises the potential use of aptamers in the diagnosis and treatment of PC.
机译:胰腺癌(PC)具有较低的5年生存率较低的恶性恶性。 PC目前没有良好的早期诊断标志物和化学治疗药物的反应。寻求更好的生物标记和发展更有效的化疗是改善PC患者医疗保健的重要途径。适体是单链核酸,具有高结合亲和力和靶分子的特异性。针对诊断和治疗用途选择了针对不同形式的癌症的许多适体。适体可以用作配体,以区分肿瘤细胞来自正常细胞。使用细胞作为选择靶标,在鉴定结合靶标后,已获得的适体在鉴定后发现新的癌症生物标记物。已显示适体具有对癌细胞增殖,细胞凋亡和转移的影响。此外,适体已被用作载体以提供治疗剂以选择性杀死PC细胞。本综述总结了适体在PC诊断和治疗中的潜在使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号